Skip to main content
MACROGENICS INC logo

MACROGENICS INC — Investor Relations & Filings

Ticker · MGNX ISIN · US5560991094 LEI · 5493001KJQUA83L8MH79 US Manufacturing
Open in API
Filings indexed 894 across all filing types
Latest filing 2013-10-09 Capital/Financing Update
Country US United States of America
Listing US MGNX

About MACROGENICS INC

https://www.macrogenics.com/

MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative antibody-based therapeutics for the treatment of cancer. The company utilizes its proprietary antibody engineering platforms, including the DART (Dual-Affinity Re-Targeting) and TRIDENT technologies, to create novel product candidates. Its pipeline consists of investigational treatments such as monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific antibodies. MacroGenics maintains fully-integrated capabilities, from research and discovery through to GMP (Good Manufacturing Practice) manufacturing, to advance its portfolio of potential medicines for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
AMENDMENT NO.4 TO FORM S-1
Capital/Financing Update Classification · 100% confidence The document is titled "Amendment No. 4 to Form S-1" and is a registration statement filed with the SEC under the Securities Act of 1933. It includes detailed information about the company's business, management, risk factors, financial data, and the terms of the proposed public offering. The Form S-1 is a registration statement used for initial public offerings (IPOs) and other securities offerings. This document is not an annual report, earnings release, or any other type of financial report but rather a capital markets filing related to the company's offering of securities to the public. Therefore, it fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2013-10-09 English
Regulatory Filings 2013
Regulatory Filings
2013-10-08 English
Capital/Financing Update 2013
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to the SEC regarding a Registration Statement on Form S-1 for MacroGenics, Inc. It requests acceleration of the effective date of the Registration Statement and provides details about the distribution of the Preliminary Prospectus. This is related to a capital raising process and the filing of a registration statement for an offering. The content is not a financial report, earnings release, or management discussion, but rather an update on the capital raising process and regulatory compliance related to the offering. Therefore, it fits best under Capital/Financing Update (CAP). The document length is short and it is not announcing a report publication, so it is not RPA or RNS. Confidence is high given the clear context and terminology related to securities offering and registration statement.
2013-10-07 English
Regulatory Filings 2013
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC Division of Corporation Finance regarding a Registration Statement on Form S-1. It requests acceleration of the effective date of the Form S-1 registration statement. The content is a formal correspondence related to a securities registration filing, not a financial report, earnings release, or other detailed report. The document length is short (1720 characters) and it is clearly a regulatory communication about the filing process. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2013-10-07 English
FORM 8-A
Regulatory Filings Classification · 100% confidence The document is a Form 8-A filed with the SEC for registration of certain classes of securities under the Securities Exchange Act of 1934. It is a regulatory filing related to securities registration, not a financial report, earnings release, or management discussion. The document is short (2634 characters) and contains no financial statements or detailed financial data. It is primarily a regulatory compliance filing for securities registration. Therefore, it fits best under the category of Regulatory Filings (RNS).
2013-10-07 English
AMENDMENT #3
Capital/Financing Update Classification · 100% confidence The document is an Amendment No. 3 to a Form S-1 Registration Statement filed with the SEC. It is a registration statement for an initial public offering (IPO) of common stock by MacroGenics, Inc. The text includes detailed information typical of an S-1 filing, such as company overview, risk factors, use of proceeds, management discussion, and financial data. This type of filing is related to capital raising and securities registration, which falls under Capital/Financing Update filings. It is not an annual report, earnings release, or any other report type defined in the list. Therefore, the correct classification is Capital/Financing Update (CAP). The document length and content confirm it is a full filing, not just an announcement or certification.
2013-10-04 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.